Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
Authors:
- Soo-Yon RheeSRSoo-Yon Rhee
- Michael BoehmMBMichael Boehm
- Olga TarasovaOlga Tarasova
- Giulia Di TeodoroGiulia Di Teodoro
- Ana B. AbecasisAAAna B. Abecasis
- Anders SönnerborgASAnders Sönnerborg
- Alexander J. BaileyABAlexander J. Bailey
- Dmitry KireevDKDmitry Kireev
- Maurizio ZazziMZMaurizio Zazzi
- the EuResist Network Study GroupTGthe EuResist Network Study Group
- Robert W. ShaferRobert W. Shafer
Open Access
Abstract
Ritonavir-boosted atazanavir is an option for second-line therapy in low- and middle-income countries (LMICs). We analyzed publicly available HIV-1 protease sequences from previously PI-naïve patients with virological failure (VF) following treatment with atazanavir. Overall, 1497 patient sequences were identified, including 740 reported in 27 published studies and 757 from datasets assembled for this analysis. A total of 63% of patients received boosted atazanavir. A total of 38% had non-subtype B viruses. A total of 264 (18%) sequences had a PI drug-resistance mutation (DRM) defined as having a Stanford HIV Drug Resistance Database mutation penalty score. Among sequences with a DRM, nine major DRMs had a prevalence >5%: I50L (34%), M46I (33%), V82A (22%), L90M (19%), I54V (16%), N88S (10%), M46L (8%), V32I (6%), and I84V (6%). Common accessory DRMs were L33F (21%), Q58E (16%), K20T (14%), G73S (12%), L10F (10%), F53L (10%), K43T (9%), and L24I (6%). A novel nonpolymorphic mutation, L89T occurred in 8.4% of non-subtype B, but in only 0.4% of subtype B sequences. The 264 sequences included 3 (1.1%) interpreted as causing high-level, 14 (5.3%) as causing intermediate, and 27 (10.2%) as causing low-level darunavir resistance. Atazanavir selects for nine major and eight accessory DRMs, and one novel nonpolymorphic mutation occurring primarily in non-B sequences. Atazanavir-selected mutations confer low-levels of darunavir cross resistance. Clinical studies, however, are required to determine the optimal boosted PI to use for second-line and potentially later line therapy in LMICs.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI136618, 19-75-10097, PTDC/SAU-INF/31990/2017, PTDC/SAU-PUB/4018/2021)
- Russian Science Foundation (AI136618, 19-75-10097, PTDC/SAU-INF/31990/2017, PTDC/SAU-PUB/4018/2021)
- Fundação para a Ciência e Tecnologia (AI136618, 19-75-10097, PTDC/SAU-INF/31990/2017, PTDC/SAU-PUB/4018/2021)
This publication has 50 references indexed in Scilit:
- Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in NigeriaPLOS ONE, 2013
- Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment RegimensPLOS ONE, 2013
- HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease StatusThe Journal of Infectious Diseases, 2012
- Antiretroviral dynamics determines HIV evolution and predicts therapy outcomeNature Medicine, 2012
- HIV-1 Protease Mutations and Protease Inhibitor Cross-ResistanceAntimicrobial Agents and Chemotherapy, 2010
- Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South AfricaAIDS, 2010
- Selecting anti-HIV therapies based on a variety of genomic and clinical factorsBioinformatics, 2008
- Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving AtazanavirJournal of Clinical Virology, 2008
- HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid CovariationPLOS Computational Biology, 2007
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004